| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 796.20 | 10.2% | 9.9% |
| Total Income | 796.20 | 10.2% | 9.9% |
| Expenditure | 666.43 | 14.8% | 8.7% |
| PBT | 70.99 | 11.5% | 37.3% |
| Net Profit | 57.66 | 7.4% | 157.2% |
| OPM | 16.30% | 3.32pp | 0.93pp |
| NPM | 7.24% | 1.38pp | 4.15pp |
| EPS | 0.18 | 10.0% | 157.1% |
Amneal Reports Q2 2026 Financial Results, Raises Full Year Guidance
30 Jul 2026 · 30 Jul, 3:51 pm
Summary
Amneal Pharmaceuticals announced strong second quarter 2026 results, with net revenue reaching $796 million, a 10% increase year-over-year, driven by growth in both Specialty and Affordable Medicines segments. Net income saw a significant surge of 157% to $58 million, while Adjusted EBITDA grew 12% to $206 million. The company also reported a 20% increase in Adjusted diluted EPS to $0.30. Reflecting this performance, Amneal is raising its full-year 2026 guidance for net revenue, Adjusted EBITDA, and Adjusted diluted EPS, signaling confidence in its diversified portfolio and strategic initiatives, including the pending Kashiv transaction.
Key Highlights
- 1
Amneal reported second quarter 2026 net revenue of $796 million, an increase of 10% compared to $725 million in the second quarter of 2025.
- 2
Specialty net revenue increased 17% in Q2 2026, driven by key branded products.
- 3
Affordable Medicines net revenue increased 13% in Q2 2026, driven by strong performance and new product launches.
- 4
Net income attributable to Amneal Pharmaceuticals, Inc. was $58 million in Q2 2026, an increase of 157% compared to $22 million in Q2 2025.
- 5
Adjusted EBITDA in the second quarter of 2026 was $206 million, an increase of 12% compared to the second quarter of 2025.
- 6
Adjusted diluted earnings per share in Q2 2026 increased by 20% to $0.30 compared to $0.25 for the second quarter of 2025.
- 7
The company is raising its 2026 full-year guidance for net revenue, Adjusted EBITDA, and Adjusted diluted EPS.
Management Comments
Chirag Patel
Amneal delivered strong, broad-based performance in the second quarter and first half of 2026, reflecting the strength of our diversified portfolio and the contributions from multiple growth drivers. This robust first-half performance gives us confidence to raise our full-year 2026 guidance for the second time this year. We are excited about the pending Kashiv transaction, which will establish biosimilars as an important new, durable growth vertical for Amneal, further diversifying our portfolio and expanding our long-term growth opportunities. As we look ahead to the remainder of 2026, 2027 and beyond, we remain highly confident in Amneal’s outlook and the breadth and durability of the opportunities across our portfolio.
Chintu Patel
Amneal delivered strong, broad-based performance in the second quarter and first half of 2026, reflecting the strength of our diversified portfolio and the contributions from multiple growth drivers. This robust first-half performance gives us confidence to raise our full-year 2026 guidance for the second time this year. We are excited about the pending Kashiv transaction, which will establish biosimilars as an important new, durable growth vertical for Amneal, further diversifying our portfolio and expanding our long-term growth opportunities. As we look ahead to the remainder of 2026, 2027 and beyond, we remain highly confident in Amneal’s outlook and the breadth and durability of the opportunities across our portfolio.
Informational and educational content only. Not investment advice.